http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-116474-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8281ac9f4fb11f15a5da018344453338 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-147 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-048 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-147 |
| filingDate | 2019-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2ccdcd05661a92218ec398fcd7a11c1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc624520492619a12bcb8247b02af117 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90b742bfd89cef8fcedaa7ab833708ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59c79fd34cb3c5cd07f1be93696003bf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e8a3f3873f5921eb9f57df16e0757df |
| publicationDate | 2021-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-116474-A1 |
| titleOfInvention | 6,7-DIHYDRO-2H-BENZOFUR [2,3-a] QUINOLIZIN-3-CARBOXYL ACID DERIVATIVES AS ANTIVIRAL AGENTS FOR THE TREATMENT OR PREVENTION OF HBV INFECTION |
| abstract | Compounds derived from 6,7-dihydro-2H-benzofuro [2,3-a] quinolizine-3-carboxylic acid as antiviral agents for the treatment or prevention of an infection with the hepatitis B virus (HBV), using the same in combined therapies with other agents with antiviral activity. Further provided is a pharmaceutical composition comprising these compounds. Claim 1: A compound represented by formula (1), or a pharmaceutically acceptable salt thereof, where: Z¹ is O, NR¹ or S; Z² is N or CR²; Z³ is N or CR³; Z⁴ is N or CR⁴, Z⁵ is N or CR⁵; R¹ is hydrogen, optionally substituted C₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted 3- to 8-membered heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; R², R³, R⁴ and R⁵ are independently selected: 1) hydrogen; 2) halogen; 3) -NO₂; 4) cyano; 5) optionally substituted C₁₋₈ alkyl; 6) optionally substituted C₂₋₈ alkenyl; 7) optionally substituted C₂₋₈ alkynyl; 8) optionally substituted C₃₋₈ cycloalkyl; 9) optionally substituted 3- to 8-membered heterocycloalkyl; 10) optionally substituted aryl; 11) optionally substituted arylalkyl; 12) optionally substituted heteroaryl; 13) optionally substituted heteroarylalkyl; 14) -SR¹¹; 15) -S (O) ₂R¹¹; 16) -S (O) ₂N (R¹¹) (R¹²); 17) -C (O) R¹¹; 18) -C (O) OR¹¹; 19) -C (O) N (R¹¹) (R¹²); 20) -C (O) N (R¹¹) S (O) ₂ (R¹²); 21) -N (R¹¹) (R¹²); 22) -N (R¹³) C (O) N (R¹¹) (R¹²); 23) -N (R¹¹) C (O) (R¹²); 24) -N (R¹¹) C (O) ₂ (R¹²); 25) -N (R¹³) S (O) ₂N (R¹¹) (R¹²); 26) -N (R¹¹) S (O) ₂ (R¹²); 27) -OR¹¹; 28) -OC (O) R¹¹; 29) -OC (O) OR¹¹; and 30) -OC (O) N (R¹¹) (R¹²); where R¹¹, R¹² and R¹³ are each independently selected from hydrogen, optionally substituted C₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted 3- to 8-membered heterocycloalkyl, optionally substituted aryl and optionally substituted heteroaryl; alternatively, R¹¹ and R¹² are taken together with the nitrogen atom to which they are attached to form an optionally substituted 3-8 membered heterocyclic ring containing 0, 1, 2 or 3 double bonds; alternatively, Z² is CR², Z³ is CR³, and R² and R³ are taken together to form an optionally substituted 3-8 membered carbocyclic or heterocyclic ring containing 0, 1, 2 or 3 double bonds; alternatively, Z³ is CR³, Z⁴ is CR⁴, and R³ and R⁴ are taken together to form an optionally substituted 3-8 membered carbocyclic or heterocyclic ring containing 0, 1, 2 or 3 double bonds; alternatively, Z⁴ is CR⁴, Z⁵ is CR⁵, and R⁴ and R⁵ are taken together to form an optionally substituted 3-8 membered carbocyclic or heterocyclic ring containing 0, 1, 2, or 3 double bonds; Q¹, Q², Q³, and Q⁴ are each independently selected from hydrogen, halo, NR¹¹, optionally substituted C₁₋₆ alkyl, optionally substituted C₁₋₆ alkoxy, optionally substituted C₃₋₈ cycloalkyl; optionally substituted 3- to 8-membered heterocycloalkyl; optionally substituted aryl and optionally substituted heteroaryl; alternatively, Q¹ is taken together with Q² or Q³ to form an optionally substituted 3-8 membered carbocyclic or heterocyclic ring containing 0, 1, 2 or 3 double bonds; alternatively, Q² is taken together with Q⁴ to form an optionally substituted 3-8 membered heterocyclic or carbocyclic ring containing 0, 1, 2 or 3 double bonds; alternatively, Q³ and Q⁴ are taken together to form an optionally substituted 3-8 membered carbocyclic or heterocyclic ring containing 0, 1, 2 or 3 double bonds; Y¹ is hydrogen, halo, or optionally substituted C₁₋₆ alkyl; Y² is O, NR¹¹, N (OR¹¹), or N (NR¹¹); Y³ is -COOR¹¹, -C (O) NHSO₂R¹¹, -C (O) NHSO₂NR¹¹R¹², 5-tetrazolyl or 1,2,4-oxadiazol-3-yl-5 (4H) -one; and Y⁴ is hydrogen or optionally substituted methyl; alternatively, Y² and Y³ are taken together to form an optionally substituted 5-12 membered heterocyclic ring containing 1, 2 or 3 double bonds. |
| priorityDate | 2018-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.